Novo Nordisk (NYSE: NVO) announced at ESC Congress 2026 that its Phase 3 ZEUS trial of ziltivekimab (an anti-IL-6 monoclonal antibody in development for cardiovascular risk reduction in inflammation-driven disease) failed to reduce major adverse cardiovascular events (MACE) versus placebo in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and inflammation (hsCRP ≥2 mg/L). The three-component MACE primary endpoint hazard ratio was 0.99 (95% CI 0.88-1.11), despite confirmed IL-6 pathway engagement (reductions in free IL-6 and hsCRP as expected). Safety was broadly similar between arms though serious infections were more frequent on ziltivekimab (consistent with the IL-6 class). NVO shares fell more than 9% on the readout, deepening the widening H1 2026 GLP-1 revenue gap that already sat at $10.2 billion versus Eli Lilly. Novo has committed to continuing the two other cardiovascular outcomes trials (HERMES in heart failure, ARTEMIS post-acute MI) with H1 2027 readouts. The ZEUS miss casts doubt on the broader thesis of anti-inflammatory cardiovascular risk reduction via IL-6 blockade.
The Factor XIa inhibitor milvexian (an oral small-molecule antithrombotic co-developed by Bristol Myers Squibb (NYSE: BMY) and Janssen) failed to reduce major adverse cardiovascular events versus placebo when added to standard antiplatelet therapy after recent acute coronary syndrome (ACS) in the Phase 3 LIBREXIA ACS trial presented in a Hot Line Session at ESC Congress 2026 Saturday August 29. The primary endpoint (cardiovascular death, myocardial infarction, or ischemic stroke) occurred in 5.4% of the milvexian arm versus 5.1% on placebo. Researchers observed no differences in intracranial or fatal bleeding between arms, addressing safety concerns that have historically constrained anticoagulant use in the post-ACS setting. The LIBREXIA program continues to assess milvexian in stroke and atrial fibrillation. The Factor XIa class as a whole (also including Bayer-Janssen's asundexian and Anthos Therapeutics' abelacimab) has struggled to demonstrate clean cardiovascular benefit at low bleeding cost.
The STAREE trial (a double-blind Australian primary-prevention trial in adults 70 and older) presented Saturday August 29, 2026 at ESC Congress 2026 Munich and simultaneously published in NEJM showed atorvastatin 40 mg daily reduced major cardiovascular events (cardiovascular death, nonfatal myocardial infarction, stroke, or coronary revascularization) by approximately 30% versus placebo over 5.9 years median follow-up in 9,971 participants (mean age 74.7, 52% women). The co-primary endpoint of disability-free survival (survival free of dementia and physical disability) did not reach statistical significance. Muscle, liver, and diabetes-related adverse events were more common on atorvastatin, though serious adverse events were balanced. STAREE addresses a long-standing evidence gap on statin efficacy in older adults without known cardiovascular disease, diabetes, or dementia. Not a peptide, but the trial matters for peptide-industry readers because it reframes the primary-prevention benefit-risk calculus that will need to be modeled for cardiovascular outcome trials of peptide obesity therapies in older populations.
Novartis (NYSE: NVS) reiterated at ESC Congress 2026 Saturday August 29 that it will advance the Phase 3 program for pacibekitug (an anti-IL-6 monoclonal antibody acquired from Tourmaline Bio through the $1.4 billion acquisition completed earlier in 2026) for cardiovascular risk reduction in inflammation-driven disease, notwithstanding the Phase 3 ZEUS trial failure of Novo Nordisk's ziltivekimab announced the same weekend. Novartis's stance is that ZEUS was underpowered in the specific ASCVD-plus-CKD-plus-inflammation subgroup rather than a class-level miss for IL-6 blockade, and that pacibekitug's differentiated pharmacokinetic profile (longer half-life and less frequent dosing) plus the differently-selected patient population in the planned Phase 3 will allow the mechanism to prove out. The commitment is a $1.4 billion acquisition-scale bet against the base-rate signal from ZEUS and continues the pattern of large pharma anti-inflammatory cardiovascular pipeline commitment following the earlier successful CANTOS canakinumab (IL-1β) proof of concept.
AbCellera Biologics (NASDAQ: ABCL) announced Wednesday August 12, 2026 the pricing of an oversubscribed underwritten public offering of 17,435,897 common shares at $9.75 per share and pre-funded warrants to purchase up to 3,076,926 shares at $9.74999 per pre-funded warrant, for aggregate gross proceeds of approximately $200 million. Net proceeds of approximately $187 million are targeted to advance clinical development of lead program ABCL635 (an antibody-based candidate for vasomotor symptoms of menopause and related endocrine indications) plus additional immunology and oncology candidates. The offering closed August 14. AbCellera is a clinical-stage biotechnology company focused on discovering first-in-class antibody-based medicines in endocrinology, women's health, immunology, and oncology using its integrated antibody-discovery platform. Not a peptide company, but the offering is included here because AbCellera's platform overlaps with peptide-discovery approaches in the same discovery-to-clinical translation ecosystem, and the H2 2026 biotech financing window (which has already delivered Parabilis's $670M peptide IPO, Kardigan's $400M+ cardio IPO, and now AbCellera's $200M follow-on) reflects continued institutional appetite for platform-derived biologics.
The FDA approved Gilead Sciences (NASDAQ: GILD) Bixlenvo (bictegravir 75 mg / lenacapavir 50 mg, a once-daily single-tablet HIV regimen) on Wednesday August 27, 2026 for adults with HIV-1 who are virologically suppressed on a stable antiretroviral regimen for at least 6 months and have no history of treatment failure or known resistance to bictegravir or lenacapavir. Approval was based on the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials presented at CROI 2026, both of which met non-inferiority for virologic suppression at Week 48 with a tolerable safety profile. Lenacapavir is Gilead's first-in-class HIV-1 capsid inhibitor (already approved as long-acting subcutaneous Sunlenca), and Bixlenvo is the first oral single-tablet regimen anchored on capsid inhibition. Dosing requires a two-day initiation period with Sunlenca before switching to Bixlenvo alone. The approval extends the single-tablet regimen category to an estimated 5%+ of U.S. HIV-suppressed adults on complex multi-pill regimens who could not previously use one-tablet options.
Roivant Sciences (NASDAQ: ROIV) subsidiary Priovant Therapeutics announced FDA approval of Lisraya (brepocitinib 30 mg once daily, a first-in-class TYK2/JAK1 dual selective inhibitor) on Wednesday August 27, 2026 for adults with dermatomyositis (DM), an autoimmune inflammatory myopathy with skin involvement and few effective targeted therapies. Approval was based on the 52-week Phase 3 VALOR trial (241 patients, the longest and largest interventional DM study), where 55% of Lisraya patients achieved moderate-or-better improvement on the Total Improvement Score with minimal-or-no steroid use versus 30% on placebo. VALOR results were published in NEJM in March 2026 with dermatology secondary endpoints in JAMA Dermatology in August 2026. List price is $35,000 for a 30-day supply, with a $0/month patient support program for eligible patients. Brepocitinib was originally discovered by Pfizer and licensed to Priovant. Not a peptide; the approval matters here because dermatomyositis is one of several autoimmune indications where peptide immunomodulators (thymalfasin, thymosin alpha-1 analogs) had been discussed in earlier decades before being displaced by targeted small-molecule and biologic approaches.
Alongside the FDA approval announcement Wednesday August 27, 2026, Roivant Sciences (NASDAQ: ROIV) filed an 8-K disclosure and hosted a conference call Friday August 28, 2026 confirming that Priovant Therapeutics has fielded a dermatology-and-rheumatology-focused sales force, contracted with major specialty pharmacy distributors, and secured initial payer coverage sufficient to begin U.S. commercial launch on August 28. Priovant is a Pfizer-Roivant joint venture (Roivant 75%, Pfizer 25%) that was created in 2022 specifically to advance brepocitinib in dermatomyositis, cutaneous lupus, and non-infectious uveitis. Beyond Lisraya, Priovant's brepocitinib program continues in Phase 3 for cutaneous lupus (VALIANT) with topline data expected in H1 2027 and in Phase 2 for non-infectious uveitis. The launch is a signal event for the Roivant 'Vant' model, in which spin-out subsidiaries develop and commercialize discrete assets while remaining consolidated within the parent. Not a peptide; included because the JAK/TYK2 inhibitor category continues to displace older peptide-based immunomodulation approaches in autoimmune disease.
The FDA on Wednesday August 26, 2026 approved Rasonque (daraxonrasib, a once-daily oral pan-RAS inhibitor developed by Revolution Medicines) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multi-agent chemotherapy. Approval was based on the Phase 3 RASolute 302 trial across 500 previously-treated patients showing median overall survival of 13.2 months on Rasonque versus 6.7 months on standard chemotherapy. The drug does not require a companion diagnostic and is approved for patients with or without an identifiable RAS tumor mutation. FDA granted Breakthrough Therapy and Orphan Drug designations plus Priority Review. Daraxonrasib is a small molecule and not a peptide; the approval matters to peptide-relevant readers because it hardens the oncology backdrop the neoantigen peptide vaccine class (Merck-Moderna intismeran, individualized long-peptide programs) is entering, and because it validates a new mechanism class in a tumor where five-year survival has stalled near 13% for two decades.
Biohaven Ltd. (NYSE: BHVN) on Wednesday August 26, 2026 signed an exclusive, royalty-bearing worldwide license with SK Biopharmaceuticals for its Kv7 ion channel platform led by opakalim (BHV-7000, a selective Kv7.2/7.3 potassium channel activator in Phase 2/3 for focal epilepsy). Deal terms: upfront and milestone payments up to $795 million plus tiered royalties from the mid-teens to low twenties on U.S. net sales of opakalim, with SK Biopharmaceuticals responsible for development, regulatory filings, and commercialization in the United States, Europe, and Japan. The Phase 2/3 RISE3 trial for opakalim is ongoing with topline data expected in H2 2026. Biohaven shares jumped roughly 13% on the announcement. Opakalim is a small-molecule ion channel activator and not a peptide; the deal is included here because it is one of the largest neuroscience licensing transactions of the year and continues the pattern of Korean pharma partners (SK, Hanmi, Yuhan) becoming serious in-licensing counterparties for U.S. biotechs seeking non-dilutive capital.
Nicox SA (Euronext: COX) announced Wednesday August 26, 2026 that the FDA accepted the New Drug Application for NCX 470 (bimatoprost-nitric oxide donor, a once-daily topical eye drop for the reduction of intraocular pressure in open-angle glaucoma or ocular hypertension) with a PDUFA target action date of April 30, 2027. NCX 470 combines the FDA-approved prostaglandin analog bimatoprost with a nitric-oxide-releasing moiety intended to add trabecular meshwork outflow to the standard uveoscleral outflow mechanism, and completed two positive Phase 3 studies (Mont Blanc and Denali). Not a peptide, but the readout matters as ophthalmology continues to be a Phase 3 register hub for peptide programs (Palatin's PL9643 melanocortin-4 receptor agonist for dry eye) that would follow the same combination-with-standard-of-care commercial pattern if approved.